Bioactivity of synthetic 2-halo-3-aryl-4(3H)-quinazoliniminium halides in L1210 leukemia and SK-BR-3 mammary tumor cells in vitro

Anticancer Research

Volumn 31, Issue 6, 2011, Pages 2083-2093

  Perchellet, Jean Pierre H ^a   Waters, Andrew M ^a   Perchellet, Elisabeth M ^a   Naganaboina, Vijaya K ^a   Chandra, Kusum L ^a   Desper, John ^a   Rayat, Sundeep ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

DNA interaction and fragmentation; Ki 67 expression; Macromolecule syntheses; Micronuclei; Multiple mitotic figures; Nuclei; Quinazoliniminium salts; Tumor cell proliferation

Indexed keywords

2 CHLORO 3 (4 METHOXYPHENYL)QUINAZOLIN 4(3H)IMINIUM CHLORIDE; 2 HALO 3 ARYL 4(3H)QUINAZOLINIMINIUM HALIDE; DNA; DOUBLE STRANDED DNA; ETHIDIUM BROMIDE; KI 67 ANTIGEN; LEUCINE; QUINAZOLINE; QUINAZOLINE DERIVATIVE; RNA; THYMIDINE; UNCLASSIFIED DRUG; URIDINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL METABOLISM; CELL PROLIFERATION; CHROMOSOME DAMAGE; CYTOKINESIS; DNA BINDING; DNA CLEAVAGE; DNA DEGRADATION; DNA FRAGMENTATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MICRONUCLEUS; MITOSIS INDEX; MULTINUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; HUMANS; KI-67 ANTIGEN; LEUKEMIA L1210; MICE; QUINAZOLINES;

EID: 79960458537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Horton DA, Bourne GT and Smythe ML: The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev (Washington, DC, U.S.) 103: 893-930, 2003.
2. Hess HJ, Cronin TH and Scriabine A: Antihypertensive 2-amino-4(3H)- quinazolinones. J Med Chem 11: 130-136, 1968.
3. Chen Z, Hu G, Li D, Chen J, Li Y, Zhou H and Xie Y: Synthesis and vasodilator effects of rutaecarpine analogues which might be involved transient receptor potential vanilloid subfamily, member 1 (TRPV1). Bioorg Med Chem 17: 2351-2359, 2009.
4. Kubota H, Kakefuda A, Watanabe T, Ishii N, Wada K, Masuda N, Sakamoto D and Tsukamoto S-I: Synthesis and pharmacological evaluation of 1-oxo-2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinolines and related analogues as a new class of specific bradycardic agents possessing 1(f) channel inhibitory activity. J Med Chem 46: 4728-4740, 2003.
5. Hirai S, Kikuchi H, Kim H-S, Begum K, Wataya Y, Tasaka H, Miyazawa Y, Yamamoto K and Oshima Y: Metabolites of febrifugine and its synthetic analogue by mouse liver S9 and their antimalarial activity against Plasmodium malaria parasite. J Med Chem 46: 4351-4359, 2003. (Pubitemid 37153015)
6. Gudasi KB, Shenoy RV, Vadavi RS, Patil MS and Patil SA: New lanthanide (III) complexes of biologically active 2,3-disubstituted quinazoline-4-(3H)-one: synthesis, characterization and biological studies. Indian J Chem (Sect A: Inorg Bio-inorg, Phys, Theor Anal Chem) 44A: 2247-2254, 2005. (Pubitemid 43021148)
7. Alagarsamy V: Antibacterial and antifungal activities of some novel 2,3-disubstituted quinazolin-4(3H)-ones. Indian J Pharm Sci 64: 600-603, 2002.
8. Reddy PB, Reddy SM, Reddy KL and Lingaiah P: Laboratory evaluation of antimicrobial activity of 2,3-disubstituted quinazoline (3H) 4-ones and their metal complexes. Indian Phytopathol 38: 361-364, 1985.
9. Rudolph J, Esler WP, O'Connor S, Coish PDG, Wickens PL, Brands M, Bierer DE, Bloomquist BT, Bondar G, Chen L, Chuang C-Y, Claus TH, Fathi Z, Fu W, Khire UR, Kristie JA, Liu X-G, Lowe DB, McClure AC, Michels M, Ortiz AA, Ramsden PD, Schoenleber RW, Shelekhin TE, Vakalopoulos A, Tang W, Wang L, Yi L, Gardell SJ, Livingston JN, Sweet LJ and Bullock WH: Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 50: 5202-5216, 2007. (Pubitemid 47585718)
10. Jatav V, Mishra P, Kashaw S and Stables JP: CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-y1] -2-styryl quinazoline-4(3H)-ones. Eur J Med Chem 43: 1945-1954, 2008.
11. Al-Obaid AM, Abdel-Hamide SG, El-Kashef HA, Abdel-Aziz AAM, El-Azab AS, Al-Khamees HA and El-Subbagh HI: Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs. Eur J Med Chem 44: 2379-2391, 2009.
12. Giri RS, Thaker HM, Giordano T, Williams J, Rogers D, Sudersanam V and Vasu KK: Design, synthesis and characterization of novel 2-(2,4-disubstituted- thiazole-5-yl)-3-aryl-3H-quinazolin-4-one derivatives as inhibitors of NF-κB and AP-1 mediated transcription activation and as potential anti-inflammatory agents. Eur J Med Chem 44: 4783, 2009.
13. Chandrika PM, Yakaiah T, Rao ARR, Narsaiah B, Reddy NC, Sridhar V and Rao JV: Synthesis of novel 4,6-disubstituted quinazoline derivatives, their anti-inflammatory and anticancer activity (cytotoxic) against U937 leukemia cell lines. Eur J Med Chem 43: 846-852, 2008. (Pubitemid 351447327)
14. Kumar A, Sharma S, Archana, Bajaj K, Sharma S, Panwar H, Singh T and Srivastava VK: Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors. Bioorg Med Chem 11: 5293-5299, 2003. (Pubitemid 37353016)
15. Sindrup SH, Graf A and Sfikas N: The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomized, controlled trial. Eur J Pain (Amsterdam, Neth) 10: 567-571, 2006. (Pubitemid 43947641)
16. Patel SV, Patel MP and Patel RG: Synthesis and characterization of heterocyclic substituted fluoran compounds. J Serb Chem Soc 72: 1039-1044, 2007.
17. Patel VH, Patel MP and Patel RG: Disperse dyes based on 2-methyl-3-[3′-arninophthalimido]-4(3H)-quinazolinone. J Serb Chem Soc 67: 719-726, 2002.
18. Luo H-Y, Zhang X-B, He C-L, Shen G-L and Yu R-Q: Synthesis of dipicolylamino substituted quinazoline as chemosensor for cobalt (II) recognition based on excited-state intramolecular proton transfer. Spectrochim Acta (Part A: Mol Biomol Spectroscopy) 70A: 337-342, 2008.
19. Jaen JC, Gregor VE, Lee C, Davis R and Emmerling M: Acetylcholinesterase inhibition by fused dihydroquinazoline compounds. Bioorg Med Chem Lett 6: 737-742, 1996. (Pubitemid 26107909)
20. Decker M, Kraus B and Heilmann J: Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties. Bioorg Med Chem 16: 4252-4261, 2008. (Pubitemid 351539052)
21. Decker M: Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem 49: 5411-5413, 2006.
22. Decker M, Krauth F and Lehmann J: Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as Cholinesterase inhibitors with selectivity towards butyrylcholinesterase. Bioorg Med Chem 14: 1966-1977, 2006.
23. Perchellet EM, Crow KR, Gakhar G, Nguyen TA, Shi A, Hua DH and Perchellet J-P: Bioactivity and molecular targets of novel substituted quinolines in murine and human tumor cell lines in vitro. Int J Oncology 36: 673-688, 2010.
24. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
25. Cory AH, Owen JC, Barltrop JA and Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212, 1991.
26. Morgan AR, Lee JS, Pulleyblank DS, Murray NL and Evans DH: Ethidium fluorescence assays. Part 1. Physico-chemical studies. Nucleic Acids Res 7: 547-569, 1979.
27. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S and E. Zeiger E: HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res 534: 65-75, 2003.
28. Lieu C-H, Chang Y-N and Lai Y-K: Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochem Pharmacol 53: 1587-1596, 1997. (Pubitemid 27356087)
29. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
30. Baguley BC and Le Bret M: Quenching of DNA-ethidium fluorescence by amsacrine and other antitumor agents: a possible electron-transfer effect. Biochemistry 23: 937-943, 1984. (Pubitemid 14168073)
31. Denny WA, Twigden SJ and Baguley BC: Steric constraints for DNA binding and biological activity in the amsacrine series. Anticancer Drug Des 1: 125-132, 1986. (Pubitemid 16109225)
32. Snyder JG, Hartman NG, Langlois D'Estantoit B, Kennard O, Remeta DP and Breslauer KJ: Binding of actinomycin D to DNA: evidence for a nonclassical high-affinity binding mode that does not require GpC sites. Proc Natl Acad Sci USA 86: 3968-3972, 1989. (Pubitemid 19154726)
33. Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81: 1361-1365, 1984. (Pubitemid 14173469)
34. Wu MH and Yung BY: Cell cycle phase-dependent cytotoxicity of actinomycin D in HeLa cells. Eur J Pharmacol 270: 203-212, 1994.
35. Insaf SS, Danks MK and Witiak DT: A structure-function analysis of DNA topoisomerase II inhibitors. Curr Med Chem 3: 437-466, 1996. (Pubitemid 27034013)
36. Nagata S: Apoptotic DNA fragmentation. Exp Cell Res 256: 12-18, 2000.
37. Perchellet EM, Ward MM, Skaltsounis A-L, Kostakis IK, Pouli N, Marakos P and Perchellet J-P: Antiproliferative and proapoptotic activities of pyranoxanthenones, pyranothioxanthe-nones and their pyrazole-fused derivatives in HL-60 cells. Anticancer Res 26: 2791-2804, 2006. (Pubitemid 44161766)
38. Shi Q and King RW: Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038-1042, 2005. (Pubitemid 41486986)